Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy

NCT03231878 is registered in ClinicalTrials.gov with Minoryx Therapeutics, S.L. as lead sponsor.

NCT NCT03231878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03231878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Lead sponsor
Minoryx Therapeutics, S.L.
Phase
Phase 2/3
Overall status
Completed
Start date
December 8, 2017
Completion date
March 6, 2025
Enrollment
105 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adrenoleukodystrophy